Clinical trial · Observational
Cardiomyopathy Tissue Bank in a Cancer Population
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this laboratory research study is to collect and store blood and tissue from patients who have a diagnosis of heart disease and may be at a high risk for the development of heart failure. This blood may be used in the future to identify genes that may play a role in developing congestive heart failure (CHF) from chemotherapy or other sources. This is an investigational study. All will be enrolled at MD Anderson.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Heart Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Sample | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Heart Disease Patients
- interventionNames
- Procedure: Blood Sample
Primary outcomes (2)
- measure
- Baseline Patient Demographic Information (age, sex, race)
- timeFrame
- One time visit.
- measure
- Identification biological markers predisposing cancer patients to development of chemotherapy-induced congestive heart failure
- timeFrame
- One time visit for collection of blood and tissue samples.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Months
Show eligibility criteria text
Inclusion Criteria: * Patients who are at high risk for developing Cardiomyopathy or Congestive Heart Failure. * Patients two months of age and older. Exclusion Criteria: * Those that are not willing to sign an informed consent.
References
Publications (0)
Data not yet available